Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology: *vu65st*_ga*MTMwMzM0NDE5OC4xNjQ0ODQ4MDk3*_ga_T874FCJ3LG*MTY2NTM5MDE2Mi4zMzAuMS4xNjY1MzkwNzM2LjAuMC4w

Dr James Januzzi (Massachusetts General Hospital, US) outlines the findings of the PROVE-HF study, a trial which aimed to determine the effect of sacubitril/valsartan therapy on cardiac biomarkers in patients with mitral regurgitation in heart failure with reduced ejection fraction.

Questions:
1. What was the ideology behind PROVE-HF?
2. What is the mechanism of action behind sacubitril/valsartan?
2. What was the study design and patient population?
3. What were the key results?
4. How should these findings impact clinical practice?
5. Where are the knowledge gaps, and what further research is needed?

Recorded remotely from Boston, 2022.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "HFSA 2022: PROVE-HF: Effect of Sacubitril/Valsartan in HFrEF Pts With MR | Dr James L Januzzi" передвинте ползунок вправо